Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$7.28 USD
-0.16 (-2.15%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fulcrum Therapeutics, Inc. (FULC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.25 | $19.00 | $5.00 | 82.01% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Fulcrum Therapeutics, Inc. comes to $13.25. The forecasts range from a low of $5.00 to a high of $19.00. The average price target represents an increase of 82.01% from the last closing price of $7.28.
Analyst Price Targets (8 )
Broker Rating
Fulcrum Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 62.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 1.71 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/28/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
2/28/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 8 |
Average Target Price | $13.25 |
LT Growth Rate | 11.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.44 |